Pub. Date : 2010 Jan
PMID : 20129148
4 Functional Relationships(s)Download |
||||||
Sentence | Compound Name | Protein Name | Organism |
|||
1 | We evaluated the evidence on fosfomycin as a treatment option for infections caused by members of the family Enterobacteriaceae with advanced resistance to antimicrobial drugs, including producers of extended-spectrum beta-lactamase (ESBL). | Fosfomycin | EsbL | Escherichia coli | ||
2 | Using a provisional minimum inhibitory concentration susceptibility breakpoint of 64 mg/L or less, 1604 (96.8%) of 1657 Escherichia coli isolates producing ESBL were susceptible to fosfomycin. | Fosfomycin | EsbL | Escherichia coli | ||
3 | Similarly, 608 (81.3%) of 748 Klebsiella pneumoniae isolates producing ESBL were susceptible to fosfomycin. | Fosfomycin | EsbL | Escherichia coli | ||
4 | In two clinical studies, oral treatment with fosfomycin-trometamol was clinically effective against complicated or uncomplicated lower urinary tract infections caused by ESBL-producing E coli in, cumulatively, 75 (93.8%) of the 80 patients evaluated. | Fosfomycin | EsbL | Escherichia coli |